Brief: Oncolytics announces phase 1b study in advanced pancreatic cancer
Oct 20 (Reuters) - Oncolytics Biotech Inc ONC.TO : * Biotech inc. announces phase 1b study in advanced pancreatic cancer * Following submission to FDA, investigational new drug application is now active * Source text for Eikon ID:nPn8yMKtH * Further company coverage ONC.TO ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Announces Clinical Supply Agreement To Evaluate Pelareorep In Combination With Loqtorzi In Squamous Cell Anal Carcinoma
Brief: Oncolytics Says Pelareorep Shows Durable Survival Benefit in Anal Cancer
Brief: Oncolytics Biotech Expects Final Cohort 4 Results Of Goblet Study In Q4 2026
Brief: Oncolytics Biotech® Secures Patent Protection To Late 2040S And Provides Intellectual Property Portfolio Update
Brief: Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer